Pro Share Advisors LLC Zentalis Pharmaceuticals, Inc. Transaction History

Pro Share Advisors LLC

$36.7 Billion
Q1 2024

A detailed history of Pro Share Advisors LLC transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 15,436 shares of ZNTL stock, worth $55,106. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,436

Previous 14,162 9.0%

Holding current value

$55,106

Previous $214,000 13.55%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$10.83 - $16.49 $13,797 - $21,008	1,274 Added 9.0%	15,436 $243,000
Q4 2023 Feb 14, 2024	BUY	$9.84 - $20.13 $19,473 - $39,837	1,979 Added 16.24%	14,162 $214,000
Q3 2023 Nov 13, 2023	BUY	$19.63 - $28.29 $38,199 - $55,052	1,946 Added 19.01%	12,183 $244,000
Q2 2023 Aug 10, 2023	BUY	$17.41 - $30.05 $178,226 - $307,621	10,237 New	10,237 $288,000
Q4 2022 Feb 02, 2023	BUY	$18.07 - $25.6 $14,293 - $20,249	791 Added 7.94%	10,759 $216,000

Q3 2022 Nov 04, 2022	BUY	$20.23 - $31.73 $24,882 - $39,027	1,230 Added 14.08%	9,968 $217,000
Q2 2022 Aug 01, 2022	SELL	$17.91 - $52.25 $50,470 - $147,240	-2,818 Reduced 24.39%	8,738 $245,000
Q1 2022 May 10, 2022	SELL	$41.58 - $80.89 $116,174 - $226,006	-2,794 Reduced 19.47%	11,556 $534,000
Q4 2021 Feb 08, 2022	BUY	$66.92 - $84.79 $8,833 - $11,192	132 Added 0.93%	14,350 $1.21 Million
Q3 2021 Nov 12, 2021	SELL	$46.83 - $73.5 $85,698 - $134,505	-1,830 Reduced 11.4%	14,218 $947,000
Q2 2021 Aug 13, 2021	BUY	$37.41 - $62.25 $102,690 - $170,876	2,745 Added 20.63%	16,048 $854,000
Q1 2021 May 14, 2021	BUY	$35.69 - $52.72 $23,733 - $35,058	665 Added 5.26%	13,303 $577,000
Q4 2020 Feb 09, 2021	BUY	$31.71 - $57.97 $400,750 - $732,624	12,638 New	12,638 $656,000

Others Institutions Holding ZNTL

# of Institutions

142

Shares Held

76.3M

Call Options Held

68.2K

Put Options Held

2.3K

View Full List

About Zentalis Pharmaceuticals, Inc.

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $203M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

More about ZNTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Account

Pro Share Advisors LLC Zentalis Pharmaceuticals, Inc. Transaction History